Product
CRV-101
1 clinical trial
2 indications
Indication
Herpes ZosterIndication
Herpes zosterClinical trial
A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderStatus: Active (not recruiting), Estimated PCD: 2024-10-04